Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Background: In Crohn’s disease and ulcerative colitis, the anti-α4β7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as...

全面介紹

書目詳細資料

Principais autores:	Laura Besendorf, Tanja M. Müller, Carol-Immanuel Geppert, Ines Schneider, Laura Mühl, Imke Atreya, Francesco Vitali, Raja Atreya, Markus F. Neurath, Sebastian Zundler
格式:	Artigo
語言:	Inglês
出版:	SAGE Publishing 2022-06-01
叢編:	Therapeutic Advances in Gastroenterology
在線閱讀:	https://doi.org/10.1177/17562848221098899
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!